A prescription digital therapeutic (DTx) for leukaemia patients developed by Blue Note Therapeutics has been awarded breakthrough device status by the FDA.
US medical device company Abbott has said it plans to launch a new range of 'biowearable' health devices aimed at consumers, in a move that builds on its expertise in glucose monitoring.
If the last couple of days is an indication, 2022 is already shaping up to be the year of big-ticket alliances between big pharma companies and specialists in artificial intelligence-driven
In the second part of our examination of issues that will shape the course of 2022, we’ll update the ongoing impacts of the pandemic, which have, as they did in 2021, a pervasive effect on
Digital health is unlocking new avenues for innovation across life sciences, and industry leaders are keen to tap into the potential of this burgeoning area.